Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,053 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.
Shlay JC, Visnegarwala F, Bartsch G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan S; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Shlay JC, et al. Among authors: peng g. J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):147-55. doi: 10.1097/01.qai.0000143599.64234.15. J Acquir Immune Defic Syndr. 2005. PMID: 15671799 Clinical Trial.
Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.
Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, Visnegarwala F, Raghavan SS, Xiang Y, Farrough M, Perry HE, Kotler D, El-Sadr WM. Shlay JC, et al. Among authors: peng g. J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):506-17. doi: 10.1097/QAI.0b013e31804216cf. J Acquir Immune Defic Syndr. 2007. PMID: 17325603 Clinical Trial.
Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy.
Gibert CL, Shlay JC, Sharma S, Bartsch G, Peng G, Grunfeld C; Terry Beirn Community Programs for Clinical Research on AIDS; International Network for Strategic Initiatives in Global HIV Trials. Gibert CL, et al. Among authors: peng g. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):44-53. doi: 10.1097/QAI.0b013e31818ce808. J Acquir Immune Defic Syndr. 2009. PMID: 19295334
The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.
Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Shlay JC, et al. Among authors: peng g. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. doi: 10.1097/QAI.0b013e3181aa1308. J Acquir Immune Defic Syndr. 2009. PMID: 19412117 Free PMC article. Clinical Trial.
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases.
Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, Abrams DI, MacArthur RD, Henry K, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Baker JV, et al. Among authors: peng g. J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):541-6. doi: 10.1097/QAI.0b013e31817bebb3. J Acquir Immune Defic Syndr. 2008. PMID: 18645520 Free PMC article.
Continuous antiretroviral therapy decreases bone mineral density.
Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD; INSIGHT SMART Body Composition Substudy Group. Grund B, et al. Among authors: peng g. AIDS. 2009 Jul 31;23(12):1519-29. doi: 10.1097/QAD.0b013e32832c1792. AIDS. 2009. PMID: 19531929 Free PMC article. Clinical Trial.
A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.
Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, Franchino B, Gibert CL, El-Sadr W, Hafner R, Korvick J, Ropka M, Heifets L, Clotfelter J, Munroe D, Horsburgh CR Jr. Cohn DL, et al. Among authors: peng gt. Clin Infect Dis. 1999 Jul;29(1):125-33. doi: 10.1086/520141. Clin Infect Dis. 1999. PMID: 10433575 Clinical Trial.
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Kozal MJ, et al. Among authors: peng g. HIV Clin Trials. 2007 Nov-Dec;8(6):357-70. doi: 10.1310/hct0806-357. HIV Clin Trials. 2007. PMID: 18042501 Clinical Trial.
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). MacArthur RD, et al. Among authors: peng g. Lancet. 2006 Dec 16;368(9553):2125-35. doi: 10.1016/S0140-6736(06)69861-9. Lancet. 2006. PMID: 17174704 Clinical Trial.
3,053 results